TP53 and posterior cortical atrophy: Currently, clinical trials investigating these drugs are mostly phase I/II basket trials that recruit different patient populations with solid malignancies (i.e., NCT04585750, NCT06386146, NCT03975387, and NCT02264613), and few preclinical and clinical trials exist for PCa that evaluate p53 as a therapeutic target (Table 2).